How Investors May Respond To Thermo Fisher Scientific (TMO) Expanding Its Cell Therapy And Biologics Platforms

• In late March and early April 2026, Thermo Fisher Scientific launched new Gibco cell therapy and CHOvantage biologics platforms, unveiled the Glacios 3 cryo-TEM, and entered a collaboration with SHL Medical to expand U.S.-based drug-device combination manufacturing capabilities.
• Together, these moves deepen Thermo Fisher’s role across high-value biomanufacturing and advanced research workflows, reinforcing its position as an integrated partner to biopharma and cell and gene therapy developers.
• We’ll now examine how the new CTS Compleo cell therapy system could influence Thermo Fisher’s broader investment narrative and growth profile.

Uncover the next big thing with 32 elite penny stocks that balance risk and reward.

Thermo Fisher Scientific Investment Narrative Recap

To own Thermo Fisher, you generally need to believe in its role as a core supplier to biopharma, cell and gene therapy, and advanced research. The recent CTS Compleo, CHOvantage, Glacios 3, and SHL Medical updates all speak to that theme. They may help offset softness in academic and government budgets and pressure in Analytical Instruments, but they do not fundamentally change the near term risk around tariffs, China exposure, and margin headwinds.

Among the latest announcements, the CTS Compleo Fill and Finish System is especially relevant. It deepens Thermo Fisher’s position in cell therapy manufacturing by automating a fragile, high risk step and tying into its broader Gibco CTS ecosystem of instruments, consumables, and services. For investors focused on catalysts, this kind of workflow integration is closely linked to the company’s ambition to be an end to end partner in higher value CDMO and bioproduction markets.

Yet investors should also weigh how tariff risk and China exposure could affect these promising new platforms...

Read the full narrative on Thermo Fisher Scientific (it's free!)

Thermo Fisher Scientific's narrative projects $50.0 billion revenue and $9.0 billion earnings by 2028. This requires 5.0% yearly revenue growth and a $2.4 billion earnings increase from $6.6 billion today.

Uncover how Thermo Fisher Scientific's forecasts yield a $663.96 fair value, a 36% upside to its current price.

Exploring Other Perspectives

While the consensus story focuses on steady growth, the most optimistic analysts see tools like CTS Compleo supporting revenue around US$55.9 billion and earnings near US$9.9 billion by 2029, which is a far more upbeat narrative than one that highlights tariff and China risks as potential brakes on Thermo Fisher’s progress.

Explore 10 other fair value estimates on Thermo Fisher Scientific - why the stock might be worth 16% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Thermo Fisher Scientific research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Thermo Fisher Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Thermo Fisher Scientific's overall financial health at a glance.

Interested In Other Possibilities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 27 companies in the world exploring or producing it. Find the list for free.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com